Published in Nat Rev Immunol on May 01, 2006
Graves' ophthalmopathy. N Engl J Med (2010) 4.24
B lymphocytes: how they develop and function. Blood (2008) 4.07
IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A (2008) 2.99
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med (2012) 2.36
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res (2007) 2.00
Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 1.95
The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther (2008) 1.68
Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis (2007) 1.65
Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes (2008) 1.63
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol (2008) 1.58
Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther (2011) 1.53
Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol (2013) 1.41
Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis (2010) 1.36
What is MRI bone oedema in rheumatoid arthritis and why does it matter? Arthritis Res Ther (2006) 1.35
TLR and B cell receptor signals to B cells differentially program primary and memory Th1 responses to Salmonella enterica. J Immunol (2010) 1.30
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. Immunity (2012) 1.21
Activation-induced cytidine deaminase deficiency causes organ-specific autoimmune disease. PLoS One (2008) 1.21
Clinical consequences of defects in B-cell development. J Allergy Clin Immunol (2010) 1.19
Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm (2009) 1.17
B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest (2012) 1.17
Mechanisms of action of CD20 antibodies. Am J Cancer Res (2012) 1.15
The contribution of B cells to renal interstitial inflammation. Am J Pathol (2007) 1.14
Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare. Br Dent J (2015) 1.13
Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol (2012) 1.12
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol (2016) 1.08
A case-control study of rheumatoid arthritis identifies an associated single nucleotide polymorphism in the NCF4 gene, supporting a role for the NADPH-oxidase complex in autoimmunity. Arthritis Res Ther (2007) 1.07
Genetic deficiency of Syk protects mice from autoantibody-induced arthritis. Arthritis Rheum (2010) 1.07
Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol (2009) 1.07
IL-10 is critically involved in mycobacterial HSP70 induced suppression of proteoglycan-induced arthritis. PLoS One (2009) 1.05
Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther (2009) 1.04
Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum (2007) 1.04
Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease. J Leukoc Biol (2015) 1.03
Increased frequency of EBV-specific effector memory CD8+ T cells correlates with higher viral load in rheumatoid arthritis. J Immunol (2008) 1.02
Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. J Clin Invest (2012) 1.00
Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol (2011) 1.00
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther (2013) 0.99
4-1BB signaling beyond T cells. Cell Mol Immunol (2011) 0.99
Clearance of pathological antibodies using biomimetic nanoparticles. Proc Natl Acad Sci U S A (2014) 0.99
Label-free characterization of white blood cells by measuring 3D refractive index maps. Biomed Opt Express (2015) 0.98
B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: A therapeutic approach for APECED patients. Proc Natl Acad Sci U S A (2008) 0.98
B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol (2008) 0.98
The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int (2007) 0.98
Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract Res Clin Rheumatol (2009) 0.97
Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag (2007) 0.95
Cell therapy for autoimmune diseases. Arthritis Res Ther (2007) 0.95
Editing antigen presentation: antigen transfer between human B lymphocytes and macrophages mediated by class A scavenger receptors. J Immunol (2008) 0.95
Differential and site specific impact of B cells in the protective immune response to Mycobacterium tuberculosis in the mouse. PLoS One (2013) 0.94
The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases. Clin Exp Immunol (2011) 0.92
Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1. Blood (2008) 0.91
Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther (2012) 0.91
Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol (2010) 0.90
Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol (2011) 0.89
Recipient B cells are not required for graft-versus-host disease induction. Biol Blood Marrow Transplant (2010) 0.88
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica (2011) 0.88
Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice. Am J Pathol (2012) 0.88
Local immune response in bladder pain syndrome/interstitial cystitis ESSIC type 3C. Int Urogynecol J (2013) 0.88
Fish oil disrupts MHC class II lateral organization on the B-cell side of the immunological synapse independent of B-T cell adhesion. J Nutr Biochem (2013) 0.86
Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm (2014) 0.86
Design of targeted B cell killing agents. PLoS One (2011) 0.85
Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. Mediators Inflamm (2014) 0.85
Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice. Front Immunol (2014) 0.83
Autoimmunity as a predisposition for infectious diseases. PLoS Pathog (2010) 0.83
Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes. J Neurol (2009) 0.83
Characterization of a novel and spontaneous mouse model of inflammatory arthritis. Arthritis Res Ther (2011) 0.83
The future of biologic agents in the treatment of Sjögren's syndrome. Clin Rev Allergy Immunol (2007) 0.83
Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Open Rheumatol J (2008) 0.82
Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat Clin Pract Rheumatol (2008) 0.82
Novel receptor-derived cyclopeptides to treat heart failure caused by anti-β1-adrenoceptor antibodies in a human-analogous rat model. PLoS One (2015) 0.81
The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. Neurol Sci (2011) 0.81
Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group. Case Rep Oncol (2009) 0.81
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci (2012) 0.81
Novel applications of Rituximab in dermatological disorders. Indian Dermatol Online J (2014) 0.81
Aging and neoteny in the B lineage. Blood (2012) 0.81
Nanotherapeutic approaches for the treatment of rheumatoid arthritis. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.80
Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases. Clin Exp Immunol (2009) 0.80
Reversing B cell aging. Aging (Albany NY) (2011) 0.80
Activation-induced cytidine deaminase and aberrant germinal center selection in the development of humoral autoimmunities. Am J Pathol (2011) 0.79
Significance of intragraft CD138+ lymphocytes and p-S6RP in pediatric kidney transplant biopsies. Transplantation (2010) 0.78
Accumulation of self-reactive naïve and memory B cell reveals sequential defects in B cell tolerance checkpoints in Sjögren's syndrome. PLoS One (2014) 0.78
[Biosimilars : Current state of the build up to series production]. Z Rheumatol (2013) 0.78
Mechanisms by Which B Cells and Regulatory T Cells Influence Development of Murine Organ-Specific Autoimmune Diseases. J Clin Med (2017) 0.78
The potential effect of statins on rituximab immunotherapy. PLoS Med (2008) 0.77
Epistatic interaction between BANK1 and BLK in rheumatoid arthritis: results from a large trans-ethnic meta-analysis. PLoS One (2013) 0.77
B cells as a target of immune modulation. Ann Indian Acad Neurol (2009) 0.76
T Regulatory Cells Support Plasma Cell Populations in the Bone Marrow. Cell Rep (2017) 0.75
The B-side story in insulin resistance. Nat Med (2011) 0.75
Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord (2016) 0.75
Evaluation of ENA-6 Profile by ELISA Immunoassay in Patients with Systemic Lupus Erythematodes. Autoimmune Dis (2012) 0.75
CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients. PeerJ (2016) 0.75
Chemical Tools To Monitor and Manipulate Adaptive Immune Responses. J Am Chem Soc (2016) 0.75
Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response. J Cancer Sci Ther (2015) 0.75
To B or not to B--that is the question for myocardial infarction. Nat Med (2013) 0.75
Mixed results for novel CD20-targeted antibody. Nat Rev Drug Discov (2009) 0.75
Altered influenza virus haemagglutinin (HA)-derived peptide is potent therapy for CIA by inducing Th1 to Th2 shift. Cell Mol Immunol (2011) 0.75
Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report. Endocrinol Diabetes Metab Case Rep (2016) 0.75
The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation. Auto Immun Highlights (2016) 0.75
Expression of the inherently autoreactive idiotope 9G4 on autoantibodies to citrullinated peptides and on rheumatoid factors in patients with early and established rheumatoid arthritis. PLoS One (2014) 0.75
Blister-inducing antibodies target multiple epitopes on collagen VII in mice. J Cell Mol Med (2014) 0.75
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.11
An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum (2002) 2.54
A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum (2009) 2.19
B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis (2007) 1.42
Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology (Oxford) (2012) 0.99
B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr Dir Autoimmun (2005) 0.89
B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy. Ann Rheum Dis (2010) 0.83
Expression of B cell activating factor (BAFF) and BAFF-binding receptors in rheumatoid arthritis. J Rheumatol (2013) 0.81
Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology (Oxford) (2013) 0.79
Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab. Clin Exp Rheumatol (2012) 0.78
Response to rituximab: has the original hypothesis been confirmed? Curr Pharm Des (2015) 0.75